Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer ; volume:22 ; number:1 ; day:2 ; month:3 ; year:2022 ; pages:1-12 ; date:12.2022
BMC cancer ; 22, Heft 1 (2.3.2022), 1-12, 12.2022
- Creator
-
Krens, Stefanie D.
Erp, Nielka P. van
Groenland, Stefanie L.
Moes, Dirk Jan A. R.
Mulder, Sasja F.
Desar, Ingrid M. E.
Hulle, Tom van der
Steeghs, Neeltje
Herpen, Carla M. L. van
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-022-09338-1
- URN
-
urn:nbn:de:101:1-2022052920285928063635
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.20252025, 7:06 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Krens, Stefanie D.
- Erp, Nielka P. van
- Groenland, Stefanie L.
- Moes, Dirk Jan A. R.
- Mulder, Sasja F.
- Desar, Ingrid M. E.
- Hulle, Tom van der
- Steeghs, Neeltje
- Herpen, Carla M. L. van
- SpringerLink (Online service)
Other Objects (12)
Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens
Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma
Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma
Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
Cabozantinib : Cabozantinib in der Behandlung des fortgeschrittenen Nierenzellkarzinoms
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study
Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports
Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma
Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens
Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma
Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma
Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
Cabozantinib : Cabozantinib in der Behandlung des fortgeschrittenen Nierenzellkarzinoms
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study
Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports
Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma
Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens
Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma
Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma
Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
Cabozantinib : Cabozantinib in der Behandlung des fortgeschrittenen Nierenzellkarzinoms
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study
Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports